학술논문
Irinotecan (Iri) in combination with high-dose infusional (HDI) 5FU/FA either weekly or bi-weekly: Evidence of survival advantage and quality of life (QoL) improvement in metastatic colorectal cancer (MCRC)
Document Type
Journal
Author
Source
Subject
Language
English
ISSN
09598049